Merck Vaccine Moves Forward With Efficacy Trial, While Special Committee Tries to Salvage Thai Study "Going for Broke in Bangkok" At the recent meeting of the NIH's AIDS Vaccine Research Working Group (May 27-28, 2004), there were discussions of two…
French African Study Offers Critical Challenge to Generics Obstructionists By Mike Barr Railing Against Randall Tobias As if there were ever any legitimate doubt, it is now official: the three-in-one generic HAART pill ("Triomune," manufactured in India by the huge…
Pfizer Working Session in Bangkok---Invitation to Richard Stern and Dr. Stern's reply 15 June 2004 Ann Prochilo Pfizer and Company San Francisco, California Dear Ann: Thanks for this invitation [posted below this response] to participate in a forum in Bangkok…
Quirky PK of BI's Tipranavir May Confine Its Use to Limited Rescue Role By Rob Camp Penned in by PK Advances in HIV pharmacology can theoretically lead to improvements in HIV care. The monitoring of antiretroviral drugs including virologic, immunologic…
Abbott, Trimeris/Roche Pricing Decisions Rekindle Old R&D Cost Questions Drug R&D Estimate (Millions) Source Invirase <$100 Interviews Norvir <$100 J. Leonard Crixivan $312* Internal memos Viracept $150 SEC docs. Agenerase <$200 SEC docs. * Goozner's estimate of Merck's total investment…
Little-Noticed Ban of Little-Used Drug Triggers Little-Known Investigation By Dr. Paul C. Bellman Whither the Checks and Balances? On April 9th, a New York City treating physician, Dr. Paul C. Bellman, submitted a treatise-length letter of protest to members of…
Vicissitudes of Medicine and Marketing Take Toll on Me-Too Line Up By Rob Camp B-I the New Salvage Outfit? Pipelines are almost as delicate and fragile as the ecosystems they go trampling through, writes TAG's Antiviral Project Director Rob Camp…
Bungled T-20 Launch Claims Its First Casualties, as Losses Spread By Mike Barr The Year of Fuzeon: Trimeris Daily Share Price -- Launch to Lability Source: Wall Street Journal Curse of the "Early Terminator" This month marks the one-year anniversary…
By Rob Camp Last year's pipeline report was warm, starry eyed and exuberant. How wrong can one guy be? Blow 1: The close of the year 2003 saw the "on-hold"-ing of SCH-C, the entry inhibitor that was moribund before the…
Against the Odds, Immune-Based Therapies for HIV Slog Along By Richard Jefferys Industry "Leery" Despite more than two decades of research, there is as yet no approved immune-based therapy (IBT) for HIV infection. And while antiretrovirals continue to course through…